← Eichor
Study identifier: NCT07464730 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult

Condition: Postoperative Pulmonary Complications (PPCs)  ·  Sponsor: Region Stockholm

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

High flow nasal oxygen (HFNO) in the immediate postoperative period has been demonstrated to reduce the risk of postoperative pulmonary complications (PPC) after cardiothoracic surgery. In specific groups of patients such as the obese and after upper abdominal surgery the results are contradictive. However, there is lack of evidence if HFNO in the general high-risk patient after abdominal and non-cardiac thoracic surgery can reduce the prevalence of PPC, hypoxaemia and escalation of therapy. Therefore, the investigators aim to compare the use of HFNO with conventional oxygen therapy (COT) in high-risk patients after abdominal and non-cardiac thoracic surgery regarding postoperative pulmonary complications.

This description comes directly from the study's public registry record.

Talk to the study team

Ida-Maria Forsberg, PhD  ·  +46704381445  ·  ida-maria.forsberg@regionstockholm.se

Always discuss trial participation with your own doctor first.

Locations (1)

Karolinska University HospitalStockholm, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07464730